Market Place
Sourcing Support
Teva Pharm CEO calls for faster US generic drug approvals
18 Feb 2025 //
REUTERS
Teva agrees with Axsome to keep generic off market until 2038
11 Feb 2025 //
FIERCE PHARMA
Teva Completes Phase 3 Trial For Olanzapine LAI In Schizophrenia
10 Feb 2025 //
BUSINESSWIRE
Teva`s subdued outlook puts damper on strong 2024 results
30 Jan 2025 //
FIERCE PHARMA
Teva Reports Q4, 2024 Growth Led By Generics, Innovation
29 Jan 2025 //
GLOBENEWSWIRE
Alvotech, Teva BLA Filing Accepted For AVT05 Biosimilar To Simponi
27 Jan 2025 //
GLOBENEWSWIRE
Teva, Astellas plan to participate in IRA drug price negotiations
24 Jan 2025 //
ENDPTS
Teva To Commercialize Formycon’s Eylea Biosimilar In Europe, Israel
13 Jan 2025 //
GLOBENEWSWIRE
Samsung Bioepis, Teva Partner For Epysqli In US
10 Jan 2025 //
GLOBENEWSWIRE
Catalyst`s Teva settlement postpones arrival of Firdapse generic
09 Jan 2025 //
FIERCE PHARMA
Teva`s Generics Elagolix Receive Tentative Approval in US
02 Jan 2025 //
FDA
Teva looks to peel back the onion on mental health
02 Jan 2025 //
FIERCE PHARMA
Teva to Present at 43rd Annual J.P. Morgan Healthcare Conference
23 Dec 2024 //
GLOBENEWSWIRE
Teva Loses US Appeal to Keep Inhaler Patents on FDA Protected List
20 Dec 2024 //
REUTERS
Teva To Host Conference Call For 2024 Q4 & 2025 Guidance On Jan 29
20 Dec 2024 //
GLOBENEWSWIRE
Teva, Sanofi say bowel disease drug met primary targets
18 Dec 2024 //
PRESS RELEASE
Egis Pharma Expands Its Portfolio with a Well-Known Product Line
16 Dec 2024 //
PRESS RELEASE
Teva Launches Patient Access Program for Uninsured Inhaler Access
11 Dec 2024 //
GLOBENEWSWIRE
Pharma firm Teva to divest its business venture in Japan
07 Dec 2024 //
REUTERS
Teva to Divest Teva-Takeda Venture in Japan
05 Dec 2024 //
GLOBENEWSWIRE
Teva Presents Positive Ph 3 Trial Data for AJOVY® in Children
04 Dec 2024 //
GLOBENEWSWIRE
Teva Launches Vital Medicines Program in El Salvador
27 Nov 2024 //
ACCESSWIRE
Teva to Present at 7th Annual Evercore ISI HealthCONx Conference
25 Nov 2024 //
GLOBENEWSWIRE
Teva Tackles Antimicrobial Resistance: Key Insights on AMR
20 Nov 2024 //
ACCESSWIRE
Teva to Present at the Jefferies London Healthcare Conference
08 Nov 2024 //
GLOBENEWSWIRE
Teva Pharma`s Generics Fedratinib Receives Tentative Approval in US
07 Nov 2024 //
FDA
Hefty sales of generics boost Teva to another big quarter
07 Nov 2024 //
FIERCE PHARMA
Teva Reports Strong Q3 2024 Results, Raises Financial Outlook
06 Nov 2024 //
GLOBENEWSWIRE
Teva Pharm CEO says will work productively with Trump
06 Nov 2024 //
REUTERS
Teva Pharmaceutical sees more growth in 2025 after strong Q3
06 Nov 2024 //
REUTERS
Teva Presents Schizophrenia Research, Phase 3 SOLARIS Trial Results
01 Nov 2024 //
GLOBENEWSWIRE
Teva Presents Tardive Dyskinesia Data at Psych Congress 2024
01 Nov 2024 //
GLOBENEWSWIRE
Teva Statement on European Commission Decision; Company to Appeal
31 Oct 2024 //
GLOBENEWSWIRE
Teva hit with €463M fine over Copaxone misconduct claims in EU
30 Oct 2024 //
FIERCE PHARMA
Neuroscience of Inclusion Unlocks High-Impact Team Performance
29 Oct 2024 //
ACCESSWIRE
Alvotech And Teva Announce FDA Approval Of SELARSDI™ Presentation
22 Oct 2024 //
GLOBENEWSWIRE
Amicus Settles Galafold® Patent Litigation With Teva
17 Oct 2024 //
GLOBENEWSWIRE
Fortrea Releases Inaugural Corporate Social Responsibility Report
17 Oct 2024 //
GLOBENEWSWIRE
Teva brings biotech ethos to drug development, exec says
15 Oct 2024 //
FIERCE BIOTECH
Teva to pay $450M to settle longstanding kickback allegations
14 Oct 2024 //
FIERCE PHARMA
Teva Prolia Biosimilar Accepted For Review By FDA And EMA
08 Oct 2024 //
GLOBENEWSWIRE
Teva Launches First Generic Version of Sandostatin® LAR Depot
01 Oct 2024 //
GLOBENEWSWIRE
Teva To Host Call On Q3 2024 Financial Results On November 6
30 Sep 2024 //
GLOBENEWSWIRE
Medincell Presents New Data On Olanzapine For Schizophrenia
23 Sep 2024 //
BUSINESSWIRE
Medincell`s Partner Teva Provides UZEDY Treatment Insights
23 Sep 2024 //
BUSINESSWIRE
New Data On Switching Schizophrenia Patients To UZEDY
21 Sep 2024 //
GLOBENEWSWIRE
Teva Presents TEV-`749 Phase 3 Data For Schizophrenia
21 Sep 2024 //
GLOBENEWSWIRE
Teva to Present at the Bank of America 2024 Global Healthcare Conference
11 Sep 2024 //
GLOBENEWSWIRE
Teva resolves Baltimore`s opioid litigation with $80M settlement
09 Sep 2024 //
FIERCE PHARMA
Opioid Plaintiffs Urge Court To Reject Fee Bid By Excluded Law Firms
09 Sep 2024 //
REUTERS
Medincell’s Partner Teva Updates on Phase 3 of Olanzapine Long-Acting Injectable
05 Sep 2024 //
BUSINESSWIRE
DEA Increases Production Limits on Takeda`s Vyvanse Amid Ongoing Shortages
05 Sep 2024 //
FIERCE PHARMA
NEUCA, Polpharma, Adamed, Teva, Zentiva Partner For ESG Development.
03 Sep 2024 //
PRESS RELEASE
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
Teva Faces Fresh Copaxone Kickbacks Case From Medicare Providers
20 Aug 2024 //
FIERCE PHARMA
Teva rides growth momentum through Q2, boosts `24 sales outlook
31 Jul 2024 //
FIERCE PHARMA
Medincell`s Partner Teva Updates On Olanzapine LAI And UZEDY®
31 Jul 2024 //
BUSINESSWIRE
Teva Reports Strong Q2 Growth, Raises 2024 Guidance
31 Jul 2024 //
GLOBENEWSWIRE
Teva And Sanofi Accelerate Anti-TL1A Phase 2b Program For IBD
24 Jul 2024 //
BUSINESSWIRE
